Business
Inhibrx Reports First Quarter 2025 Financial Results
Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the first quarter of 2025. Following the completion of the sale of INBRX-101 by Inhibrx, Inc. (the "Former Parent") to Sanofi S.A. and the Former Parent's concurrent spin-off of the Inhibrx business in May 2024, the biopharmaceutical company now has two programs in ongoing clinical trials, with data readouts for each expected within the current year. Because the spin-off was accounted for a
About this update from Inhibrx Biosciences, Inc.
[{"type":"text","content":"SAN DIEGO, May 14, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the first quarter of 2025. Following the completion of the sale of INBRX-101 by Inhibrx, Inc. (the "Former Parent") to Sanofi S.A. and the Former Parent's concurrent spin-off of the Inhibrx business in May 2024, the biopharmaceutical company now has two programs in ongoing clinical trials, with data readouts for each expected within the current year. Because the spin-off was accounted for as a reverse spin-off, for periods prior to the spin-off, the Company's financial statements are the historical financial statements of the Former Parent.","length":736,"tagName":"p"},{"type":"image","alt":"Inhibrx, Inc. logo (PRNewsfoto/Inhibrx, Inc.)","displaySize":"","headline":null,"caption":"Inhibrx, Inc. logo (PRNewsfoto/Inhibrx, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":133,"url":"https://media.zenfs.com/en/prnewswire.com/fae7441a9e255131c816a20f83e3312b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/cbFWCtOSsA45e9XaqevcGQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTIzNDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/fae7441a9e255131c816a20f83e3312b","width":400,"height":133}},"href":"https://mma.prnewswire.com/media/1063194/inhibrx_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Upcoming Milestones","length":19,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"INBRX-109","length":9,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Data from the registration-enabling Phase 2 trial in unresectable or metastatic conventional chondrosarcoma are expected during the third quarter of 2025; and","length":163,"tagName":"p"}]},{"val":[{"type":"text","content":"Initial data on the colorectal cancer expansion cohort are anticipated in the third quarter of 2025 with interim data from the Ewing sarcoma expansion cohort expected in the second half of 2025.","length":194,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":357,"olType":false}]},{"val":[{"type":"text","content":"INBRX-106","length":9,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Initial Phase 2 data from the randomized Phase 2/3 trial i...